Home>Topics>Companies>Dendreon Corporation

Dendreon Corporation

  1. All
  2. Commentary
  3. Headlines
  1. UPDATE 3-Valeant eyes smaller deals to build on Salix, Dendreon purchases

    Headlines

    Mon, 23 Feb 2015

    Feb 23 (Reuters) - Valeant Pharmaceuticals International Inc plans to strike smaller deals to build on its acquisitions of Salix Pharmaceuticals Ltd and assets of Dendreon Corp , its chief executive...

  2. REFILE-UPDATE 2-Valeant to buy bankrupt vaccine maker Dendreon

    Headlines

    Wed, 11 Feb 2015

    Feb 10 (Reuters) - Valeant Pharmaceuticals International Inc will scoop up bankrupt cancer vaccine maker Dendreon Corp , after no additional qualified bids came forward by Tuesday's deadline, Valeant...

  3. UPDATE 2-Valeant to buy bankrupt vaccine maker Dendreon

    Headlines

    Tue, 10 Feb 2015

    Feb 10 (Reuters) - Valeant Pharmaceuticals International Inc will scoop up bankrupt cancer vaccine maker Dendreon Corp , after no additional qualified bids came forward by Tuesday's deadline, Valeant said.

  4. Valeant appears poised to buy bankrupt vaccine maker Dendreon -sources

    Headlines

    Tue, 10 Feb 2015

    Feb 10 (Reuters) - Valeant Pharmaceuticals International Inc appears poised to scoop up bankrupt cancer vaccine maker Dendreon Corp after another potential buyer dropped from the bidding process,...

  5. Dendreon Announces Chapter 11 Bankruptcy Filing; Discontinuing Coverage

    Commentary

    Thu, 20 Nov 2014

    cancer drug business. This news is not surprising, given the overhang from the $620 million in notes that were coming due in 2016, as the company continued to remain unprofitable despite Provenge sales of about $150 million last year.

  6. Dendreon Announces Chapter 11 Bankruptcy Filing; Placing Company Under Review

    Commentary

    Mon, 10 Nov 2014

    cancer drug business. This news is not surprising given the overhang from the $620 million in notes that were coming due in 2016, as the company continued to remain unprofitable despite Provenge sales of about $150 million last year.

  7. Second-Quarter Provenge Sales Are Solid; Convertible Debt Overhang Underscores Serious Risks

    Commentary

    Tue, 12 Aug 2014

    Dendreon reported second-quarter results ..... than our expectations, with solid Provenge sales. However, the ongoing lack ..... moat, negative trend ratings. Dendreon reported $82.2 million in Provenge sales for the quarter, a solid

  8. Another Quarter of Sluggish Provenge Sales; Convertible Debt Overhang Underscores Risks

    Commentary

    Fri, 9 May 2014

    Dendreon reported first-quarter results ..... expectations, with continued sluggish Provenge sales and lack of clarity on plans ..... moat, negative trend ratings. Dendreon reported $68.8 million in Provenge sales for the quarter, a slight

  9. Dendreon 4Q Results Show Stabilization of Sales and Highlight European Opportunity; Maintaining FVE

    Commentary

    Mon, 3 Mar 2014

    Dendreon reported fourth-quarter results ..... expectations. The stabilization of Provenge revenue and the announcement of the ..... estimate and our no-moat rating. Dendreon reported $74.8 million in Provenge sales for the quarter, up 10

  10. Dendreon shares jump on news of prostate drug's European launch

    Headlines

    Mon, 3 Mar 2014

    (Reuters) - Biotechnology company Dendreon Corp said it would start selling its prostate cancer vaccine Provenge in Europe, sending its shares up nearly 15 percent in premarket trading.

« Prev1234Next »
Content Partners